We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
-16.43%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$791B
AUM Growth
-$200B
Cap. Flow
-$11.4B
Cap. Flow %
-1.44%
Top 10 Hldgs %
26.42%
Holding
3,063
New
88
Increased
1,490
Reduced
1,207
Closed
101

Top Buys

Rank Stock Value
1
BDX icon
Becton Dickinson
BDX
+$3.46B
2
UNH icon
UnitedHealth
UNH
+$2.79B
3
CRM icon
Salesforce
CRM
+$2.38B
4
SHW icon
Sherwin-Williams
SHW
+$1.41B
5
PM icon
Philip Morris
PM
+$1.34B

Sector Composition

Rank Sector Weight
1 Technology 26.68%
2 Healthcare 19.49%
3 Consumer Discretionary 13.07%
4 Financials 11.17%
5 Communication Services 8.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
STAB
2926
DELISTED
Statera Biopharma, Inc. Common Stock
STAB
$17K ﹤0.01%
61,200
+49,500
+423% +$12.8K
HYMC icon
2927
Hycroft Mining Holding Corp
HYMC
$2.56B
$16K ﹤0.01%
+1,441
New +$21.4K
EMBK
2928
DELISTED
Embark Technology, Inc. Common Stock
EMBK
$16K ﹤0.01%
+1,575
New +$92K
CRBP icon
2929
Corbus Pharmaceuticals
CRBP
$189M
$14K ﹤0.01%
1,877
+330
+21% +$3.19K
SPIR icon
2930
Spire Global
SPIR
$571M
$14K ﹤0.01%
+1,492
New +$19.1K
DOMA
2931
DELISTED
Doma Holdings, Inc.
DOMA
$13K ﹤0.01%
+523
New +$22.2K
OTLK icon
2932
Outlook Therapeutics
OTLK
$206M
$11K ﹤0.01%
+560
New +$16.1K
AUD
2933
DELISTED
Audacy, Inc.
AUD
$10K ﹤0.01%
10,913
+400
+4% +$802
BOAC.WS
2934
DELISTED
Bluescape Opportunities Acquisition Corp. Redeemable warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
BOAC.WS
$10K ﹤0.01%
46,500
CBUS icon
2935
Cibus
CBUS
$144M
$7K ﹤0.01%
562
NMTR
2936
DELISTED
9 Meters Biopharma
NMTR
$6K ﹤0.01%
1,081
+91
+9% +$857
KALA icon
2937
KALA BIO
KALA
$17.1M
$5K ﹤0.01%
6
-46
-88% -$72.2K
ONYXW
2938
DELISTED
Onyx Acquisition Co. I Warrant
ONYXW
$5K ﹤0.01%
37,750
GVCIW
2939
DELISTED
Green Visor Financial Technology Acquisition Corp. I Warrants
GVCIW
$5K ﹤0.01%
37,925
HAACW
2940
DELISTED
Health Assurance Acquisition Corp. Warrants
HAACW
$5K ﹤0.01%
35,000
PRPC.WS
2941
DELISTED
CC Neuberger Principal Holdings III Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
PRPC.WS
$4K ﹤0.01%
12,125
MLAIW
2942
DELISTED
McLaren Technology Acquisition Corp. Warrant
MLAIW
$4K ﹤0.01%
37,750
AFACW
2943
DELISTED
Arena Fortify Acquisition Corp. Warrant
AFACW
$4K ﹤0.01%
37,500
EUCRW
2944
DELISTED
Eucrates Biomedical Acquisition Corp. Warrant
EUCRW
$2K ﹤0.01%
22,697
NBIS
2945
Nebius Group N.V.
NBIS
$70.5B
$1K ﹤0.01%
5,534,087
VELOW
2946
DELISTED
Velocity Acquisition Corp. Warrant
VELOW
$1K ﹤0.01%
11,329
AEHR icon
2947
Aehr Test Systems
AEHR
$4.22B
-12,300
Closed -$125K
ALGS icon
2948
Aligos Therapeutics
ALGS
$43.7M
-903
Closed -$49K
AMX icon
2949
America Movil
AMX
$69.7B
-9,700
Closed -$205K
ANNX icon
2950
Annexon
ANNX
$873M
-1,324,733
Closed -$3.62M

Similar funds

T. Rowe Price Associates's Q2 2022 Portfolio in Review

As of Q2 2022, T. Rowe Price Associates held 3,063 positions worth $791B, down 20% from $992B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

T. Rowe Price Associates's Q2 2022 filing shows 88 new, 1,490 increased, 1,207 reduced and 101 closed positions. Its largest new stake was ESAB: 6,073,363 shares worth $266M. The largest sale was Meta Platforms (Facebook), an estimated $4.44B.

By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • T. Rowe Price Associates's largest Q2 2022 buy was ESAB: 6,073,363 shares worth $266M.
  • T. Rowe Price Associates added most to Becton Dickinson in Q2 2022, an estimated $3.46B increase.
  • T. Rowe Price Associates's biggest Q2 2022 reduction was Meta Platforms (Facebook), cutting an estimated $4.44B.
  • T. Rowe Price Associates fully exited Ortho Clinical Diagnostics Holdings plc Ordinary Shares in Q2 2022, selling an estimated $364M.
  • T. Rowe Price Associates's ten largest holdings make up 26% of its $791B portfolio in Q2 2022.
  • T. Rowe Price Associates opened 88 new positions and closed 101 in Q2 2022.
  • T. Rowe Price Associates's portfolio value fell 20% quarter-over-quarter to $791B.

Based on T. Rowe Price Associates's 13F filing for Q2 2022, filed 15 Aug 2022.